Als With Functional Decline Therapeutics
1. Radicava patent expiration
Treatment: Treatment of amyotrophic lateral sclerosis (als)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6933310 | MITSUBISHI TANABE | Therapeutic agent for amyotrophic lateral sclerosis (ALS) |
Nov, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 05, 2022 |
| Orphan Drug Exclusivity(ODE) | May 05, 2024 |
| ODE*(ODE*) | May 05, 2024 |
| Orphan Drug Exclusivity(ODE-144) | May 05, 2024 |
Drugs and Companies using EDARAVONE ingredient
NCE-1 date: 05 May, 2021
Market Authorisation Date: 05 May, 2017
Dosage: SOLUTION
More Information on Dosage
RADICAVA family patents
